Axcella Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Axcella Therapeutics, Inc.
Scrip takes a look at major R&D trends in the Korean biotech sector in the third quarter, analysing new moves at Genexine, Bridge Biotherapeutics, Oscotec and others to cope with ongoing challenges and focus resources on the most promising projects.
Aesther Healthcare Acquisition extended the deadline to merge with Ocean Biomedical, while Intrinsic Medicine no longer plans to go public by merging with a SPAC. In restructuring news, Otonomy begins liquidation, Celyad cuts last clinical program with cash running out and Clovis files for bankruptcy.
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
Axcella’s AXA1125, a therapeutic combination of amino acids, shows liver stiffness, liver enzyme and fat reduction benefits in Phase IIb interim look, but the firm lacks the cash to complete the trial.
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Pronutria Bioscience
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.